Arbutus Biopharma Corporation (ABUS) Financials

ABUS Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 277.2 million 17.0 million
Dec. 31, 2025 94.6 million 18.0 million
Sept. 30, 2025 97.7 million 20.3 million
June 30, 2025 103.3 million 20.3 million

ABUS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -8.1 million 1.4 million
Dec. 31, 2025 -4.7 million 14.9 million
Sept. 30, 2025 -5.8 million 1.3 million
June 30, 2025 -15.7 million 864000

ABUS Net Income

No data available :(

ABUS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 95.2 million - 631000
Dec. 31, 2025 91.5 million 3.4 million 199000
Sept. 30, 2025 93.7 million - 922000
June 30, 2025 98.1 million - 1.1 million

ABUS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 195.2 million
Dec. 31, 2025 191.6 million
Sept. 30, 2025 191.8 million
June 30, 2025 192.4 million

ABUS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 4.1 million 5.9 million -
Dec. 31, 2025 4 5.0 million 3.7 million 11000
Sept. 30, 2025 - 5.8 million 3.0 million -11000
June 30, 2025 - 5.5 million 3.3 million -

ABUS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 179.1 million 11000
Dec. 31, 2025 1.1 million 11000
Sept. 30, 2025 529000 11000
June 30, 2025 10.7 million 11000

ABUS Revenue by Segment
Graph available only for paid members. Upgrade to see it.

ABUS

Price: $4.35

52 week price:
2.94
5.10

Payout Ratio Range:
-71.14%
82.21%

Earnings Per Share: 0.83 USD

P/E Ratio: 4.99

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 545700

Ebitda: -10.9 million

Market Capitalization: 817.8 million

Links: